AGMO
Alkylglycerol monooxygenase
Also known as: ALKMO_HUMAN, FLJ16237, TMEM195
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6ZNB7
- Gene
- AGMO
- Ensembl
- ENSG00000187546
- Chromosome
- 7
- Canonical length
- 445 aa
- Protein class
- Enzymes, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Vesicles
OverviewNCBI Gene
The protein encoded by this gene is a tetrahydrobiopterin- and iron-dependent enzyme that cleaves the ether bond of alkylglycerols. Sequence comparisons distinguish this protein as forming a third, distinct class of tetrahydrobiopterin-dependent enzymes. Variations in this gene have been associated with decreased glucose-stimulated insulin response, type 2 diabetes, and susceptibility to intracranial aneurysms. [provided by RefSeq, Aug 2012]
Canonical amino-acid sequenceUniProt
445 residues, UniProt reviewed canonical sequence.
>Q6ZNB7|AGMO
1 MKNPEAQQDV SVSQGFRMLF YTMKPSETSF QTLEEVPDYV KKATPFFISL MLLELVVSWI
61 LKGKPPGRLD DALTSISAGV LSRLPSLFFR SIELTSYIYI WENYRLFNLP WDSPWTWYSA
121 FLGVDFGYYW FHRMAHEVNI MWAGHQTHHS SEDYNLSTAL RQSVLQIYTS WIFYSPLALF
181 IPPSVYAVHL QFNLLYQFWI HTEVINNLGP LELILNTPSH HRVHHGRNRY CIDKNYAGVL
241 IIWDKIFGTF EAENEKVVYG LTHPINTFEP IKVQFHHLFS IWTTFWATPG FFNKFSVIFK
301 GPGWGPGKPR LGLSEEIPEV TGKEVPFSSS SSQLLKIYTV VQFALMLAFY EETFADTAAL
361 SQVTLLLRVC FIILTLTSIG FLLDQRPKAA IMETLRCLMF LMLYRFGHLK PLVPSLSSAF
421 EIVFSICIAF WGVRSMKQLT SHPWKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AGMO can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 5
- Mean surface accessibility (rSASA)
- 0.25
- Highest tissue expression
- 114 nTPM
Expression across tissuesHPA
Tissue
- liver: 114 nTPM
- small intestine: 14 nTPM
- epididymis: 14 nTPM
- duodenum: 9.1 nTPM
- kidney: 8.3 nTPM
- gallbladder: 3.4 nTPM
Single-cell type
- undifferentiated spermatogonia: 366 nCPM
- hepatocytes: 345 nCPM
- adipocytes: 212 nCPM
- proximal tubule cells: 204 nCPM
- enterocytes: 191 nCPM
- oocytes: 120 nCPM
Immune cell
- basophil: 1.4 nTPM
- neutrophil: 0.8 nTPM
- NK-cell: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- white matter: 9.1 nTPM
- basal ganglia: 5.9 nTPM
- cerebral cortex: 5.8 nTPM
- thalamus: 4.7 nTPM
- medulla oblongata: 4.3 nTPM
- pons: 4.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about AGMO.
Disease | GeneticClinVar
5 pathogenic / likely-pathogenic of 164 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- AGMO-related Neurodevelopmental disorder
- See cases
- Hypercholesterolemia, familial, 1
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.71
- gnomAD pLI
- 0
- gnomAD missense Z
- -2.56
- DepMap mean gene effect
- 0.09
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- iron ion binding
- glyceryl-ether monooxygenase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Fatty acid hydroxylase
- Fatty acid hydroxylase
- Sterol desaturase/TMEM195-like
- Alkylglycerol monooxygenase, C-terminal
- Alkylglycerol monooxygenase C-terminal domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AGMO as an antibody target. Whether an autoantibody or antibody against AGMO could matter depends on whether native AGMO is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AGMO is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label AGMO as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...